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Case 32 
A white woman in her 70s with advanced Alzheimer’s disease was referred to 33 
the hematology clinic for evaluation of a high hemoglobin (169g/L, NR 120-34 
160) and red blood cell count (5.67 x1012/L, NR 3.8-4.8) associated with a 35 
generalised itch, worse after a bath.  On examination, she had a florid, 36 
erythematous macular eruption over the trunk and limbs (Figure, A), but no 37 
hepatosplenomegaly or lymphadenopathy.  In addition to the high 38 
hemoglobin, a mild lymphocytosis (6.2 x 109/l, range 1.5-4.0) was noted with 39 
the lymphocyte morphology suggesting reactive changes.  Skin biopsy 40 
(Figure, B) showed a normal epidermis with a pericapillary infiltrate of small 41 
lymphocytes restricted to the dermis and no leucocytoclastic vasculitis, fungal 42 
organisms or dermal mucin.  The absence of cellular atypia and epidermal 43 
involvement suggested a diagnosis of lupus, or gyrate or annular erythema, 44 
and the need for clinicopathological correlation. 45 
She was commenced on a topical emmolient, steroid creams and oral 46 
antihistamines; due to a sub-optimal clinical response, skin biopsy was 47 
repeated two months after the original procedure, but the histological 48 
appearances were unchanged.  The hemoglobin continued to remain high 49 
and the lymphocyte count had increased to 9.0 x 109/l.  A representative 50 
lymphocyte is shown (Figure, C). 51 
  52 
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What is the likely diagnosis? 53 
A. Prolymphocytic leukaemia 54 
B. Advanced cutaneous T-cell lymphoma/Sézary syndrome 55 
C. Polycythemia rubra vera 56 
D. Cutaneous lupus erythematosus 57 
 58 
Diagnosis 59 
A. Prolymphocytic Leukaemia (PLL). 60 
 61 
Discussion 62 
 63 
The blood film showed an excess of medium-sized lymphocytes with a round 64 
to oval nucleus, basophilic cytoplasm and prominent nucleolus (Figure, C), 65 
appearances that typify prolymphocytes.  Immunophenotyping identified the 66 
expression of CD4 on lymphocytes along with the pan T-cell antigens CD2, 67 
CD3, CD5 and CD7, but no CD8, B cell or natural killer cell makers, 68 
supporting a diagnosis of T-PLL. 69 
 70 
T-PLL, a rare lymphoid malignancy of older people (median age 61 years) can 71 
be misdiagnosed as an alternative mature T-cell neoplasm or even a benign 72 
disorder, particularly in patients with an atypical presentation.1  Common 73 
features of T-PLL include a high lymphocytosis, bone marrow failure and 74 
splenomegaly, or lymphadenopathy, but pseudopolycythemia, mild 75 
lymphocytosis, erythroderma and pruritis in our patient made advanced 76 
cutaneous T-cell lymphoma/Sézary syndrome (CTCL) a diagnostic 77 
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consideration.1-3  However, the malignant cells in CTCL have a 78 
hyperconvulated, cerebriform nucleus, distinguishing these from 79 
prolymphocytes.  Moreover, the absence of epidermotropism and cellular 80 
atypia in the skin biopsy are characteristic of T-PLL.  The preservation of CD7 81 
expression on circulating and dermal prolymphocytes further supported a 82 
diagnosis of T-PLL over CTCL or adult T-lymphocytic leukemia/lymphoma 83 
(ATLL),2,3 an alternative possibility.  The patient’s racial origin, low 84 
expression-intensity of CD25 on neoplastic cells and absence of eosinophilia 85 
also argued against ATLL. 86 
 87 
The important learning point here is that with no unique antigen expression 88 
profile (except in a quarter of cases that co-express CD4 and CD8), the 89 
morphological recognition of circulating prolymphocytes is key to diagnosing 90 
T-PLL.1  Thus, a failure to integrate the skin biopsy appearances with blood 91 
cytomorphology could have easily become a diagnostic pitfall, particularly 92 
since cytogenetic analysis was normal and non-contributory to the diagnosis.  93 
FISH probes failed to detect inversion of chromosome 14 (q11.2q32.1), the 94 
most frequent chromosomal abnormality in T-PLL that associates with TCL1 95 
overexpression.1-3,4  Nevertheless, TCRB and TCRG gene rearrangements 96 
confirmed the T-cell population to be clonal.  Additional learning points relate 97 
to the original reason for referral to hematology: our patient was suspected to 98 
have myeloproliferative polycythemia (PRV) due to a high hemoglobin and 99 
itch, but patients with PRV generally do not have a rash.5  It is likely that fluid 100 
loss due to erythroderma caused ‘pseudopolycythaemia’ in our patient; 101 
indeed,JAK2 analysis was negative for mutations frequent in PRV.6,7  102 
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Cutaneous lupus erythematosus was unlikely as sun-exposed parts of the 103 
body were spared and typical histological features: lymphoid involvement of 104 
the dermo-epidermal junction, epithelial layer degeneration or dermal mucin 105 
deposits were absent,8 as were serum autoantibodies commonly associated 106 
with connective tissue disorders. 107 
 108 
Most patients with T-PLL require anti-leukemic therapy at presentation.  109 
Conventional chemotherapy and steroids have limited efficacy, but the anti-110 
CD52 monoclonal antibody alemtuzumab can achieve responses rates of 70-111 
90% when administered intravenously.1,2  The disease response to 112 
alemtuzumab is of prognostic significance and supersedes the use of pre-113 
treatment variables including total white count, lymphocyte-doubling-time and 114 
TCL1 expression-intensity, as an important determinant of survival.1  115 
However, responses are frequently not durable, and to optimise outcomes, 116 
consolidative treatment with autologous or allogeneic stem cell transplantation 117 
requires consideration in eligible patients.1,2  Recent reports have indicated 118 
the effectiveness of the Bcl2 antagonist venetoclax9 and JAK3 inhibitors10 119 
(following identification of JAK/STAT pathway mutations) in T-PLL, but the 120 
optimal positioning of newer drugs in treatment-algorithms requires 121 
investigation.2 122 
 123 
Our patient’s advanced cognitive impairment precluded a trial of therapy with 124 
alemtuzumab and her management focused exclusively on symptom-125 
palliation.  Eight months after the initial clinic visit, she presented with right 126 
sided periorbital swelling due to an abnormal soft tissue in the temporal and 127 
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zygomatic region compressing the eye-ball, and worsening lymphocytosis (13 128 
x 109/l).  Disease progression was rapid and she passed away in a hospice. 129 
  130 
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Figure.  A. Skin image showing erythroderma. B. Section of skin biopsy  175 
showing a pericapillary infiltrate of small lymphoid cells restricted to the 176 
dermis (haematoxylin & eosin stain, original magnification x 200).  C. Blood 177 
film image showing a typical lymphocyte (May Grünwald Giemsa stain, 178 
original magnification x 400). 179 
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